Landmark trial
INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy
Minsky BD, Pajak TF, Ginsberg RJ, et al. · RTOG / Intergroup
DoseLab summary
Intergroup phase 3 trial comparing 64.8 Gy with 50.4 Gy, both with cisplatin and 5-FU, for definitive treatment of esophageal cancer. The higher dose did not improve survival or local control, so 50.4 Gy became the standard. Citation checked against Europe PMC.
Why this is useful
Why definitive esophageal chemoradiation is usually 50.4 Gy: escalating to 64.8 Gy gave no benefit.
Reference details
- Title
- INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy
- Authors / organization
- Minsky BD, Pajak TF, Ginsberg RJ, et al. · RTOG / Intergroup
- Publication / protocol
- J Clin Oncol. 2002;20(5):1167–1174
- Version
- Pending verification
- Year
- 2002
- DOI
- 10.1200/JCO.2002.20.5.1167
- Disease sites
- GI
- Topics
- Esophagus, Definitive, Landmark trial, RTOG
- Fractionation context
- 50.4 Gy / 28 fx vs 64.8 Gy / 36 fx
- Last reviewed by DoseLab
- Pending verification